- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01005160
Drug Interaction Between CKD-501 and Metformin (CKD-19HPS09H)
A Sequence-randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between CKD-501 and Metformin After Oral Administration in Healthy Male Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Volunteers doses three times over the period of CKD-501 0.5mg and metformin 1000mg alone, repeated doses are five days.
In addition, the CKD-501 0.5mg and metformin 1000mg are administered simultaneously be used repeatedly to five days.
Every time before and after each medication safety and drug absorption, distribution, metabolism and excretion rate, and is expected to conduct some tests.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Between 20 aged and 45 aged in healthy males
- Weight more than 55kg, IBW 20% within the range
- FPG 70~125 mg/dL
- Agreement with written informed consent
Exclusion Criteria:
- Clinically significant disease(liver, heart, immune system, Respiratory system, Endocrine system, blood tumor disease, Mental illness)or a history that has learned
- Test drug may affect the absorption of the gastrointestinal disease or a history that has learned
- Hypersensitivity reactions to drugs or Clinically significant hypersensitivity reactions in the history of party
- AST, ALT level over to 1.5 times and creatinine clearance less 80mL/min
- systolic blood pressure less than 100mmHg or 150mmHg, diastolic blood pressure less than 60mmHg or greater than 95mmHg
- Substance abuse, or a history of drug abuse showed a positive for the party
- Medication within 2 weeks in the first professional medical, medicine, OTC, vitamins taking
- Previously participated in other trial within 2 months
- Medication within 2 months make whole blood donation or medication within 1 month in component blood donation
- Continued to be drunk or during clinical trials can not be drunk
- 10 cigarettes a day for the last 3 months than the average smoker or during clinical trials can not be smoke
- Containing grapefruit foods ingested during clinical trials or can not be ingested
- Containing caffeine foods ingested during 24 hours before admission to hospital of can not be ingested
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CKD501
|
CKD-501 0.5mg, metformin 1000mg
Other Names:
CKD-501 0.5mg, metformin 1000mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CKD - 501 and metformin Pharmacokinetics evaluation
Time Frame: 16 days
|
16 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CKD-501 and metformin safety evaluation
Time Frame: 16 days
|
16 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kyung S Yu, Seoul National University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CKD-19HPS09H
- 19HPS09H
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Volunteers
-
Shanghai Henlius BiotechRecruitingHealthy Male VolunteersChina
-
PMV Pharmaceuticals, IncCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.UnknownHealthy Male VolunteersKorea, Republic of
-
Bristol-Myers SquibbCompletedHealthy Male VolunteersUnited States
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthy Male VolunteersKorea, Republic of
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Allist Pharmaceuticals, Inc.CompletedHealthy Male VolunteersChina
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
ShionogiCompleted
-
Charles University, Czech RepublicCompleted
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland